Skip to content

Deoxyhypusine synthase: a new target for HIV therapy?

Tipranavir expanded access programme begins in US

Superiority of tipranavir / ritonavir confirmed in second salvage study

Atazanavir/ritonavir shows comparable efficacy to Kaletra at 96 weeks for PI-experienced patients

Double boosted protease inhibitors generate interest at Glasgow conference

Tenofovir/ddI: is CD4 cell loss on treatment linked to this combination?

Failure of three main classes of antiretrovirals present in 12% of EuroSIDA cohort

ICAAC: Tipranavir / ritonavir superior to other boosted PIs in salvage therapy

ICAAC: When to use T-20: new analysis shows risk of leaving it too late